The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alfimova M.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Kondratyev N.V.

Mental Health Research Center, Moscow, Russia

Golimbet V.E.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Results and promises of genetics of cognitive impairment in schizophrenia: epigenetic approaches

Authors:

Alfimova M.V., Kondratyev N.V., Golimbet V.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2): 130‑135

DOI: 10.17116/jnevro201711721130-135

Views: 1309

Downloaded: 31

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Alfimova MV, Kondratyev NV, Golimbet VE. Results and promises of genetics of cognitive impairment in schizophrenia: epigenetic approaches. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):130‑135. (In Russ.)
https://doi.org/10.17116/jnevro201711721130-135

 
МСФ на ЯМ
Close metadata
Recommended articles:
Willingness to expend effort for rewa­rds in indi­viduals at clinical high-risk for psychosis: a rela­tionship with the seve­rity and stability of nega­tive symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):109-115
The rela­tionship between the functional state of the brain and clinical and constitutional factors in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):123-128
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Asso­ciations between components of meta­bolic syndrome and cognitive impairment in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87
Cere­bral hemo­dynamic diso­rders in patients with schi­zophrenia with concomitant meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85
Clinical and psychopathological characteristics of patients with late-onset schi­zophrenia and schi­zophrenia-like psychoses in clusters identified by biological para­meters. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):137-144
Clinical and psychometric characteristics of cognitive and nega­tive diso­rders in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):64-71
Controversial issues of diagnosis and theoretical concepts of schi­zophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24
Psychological concepts — design of clinical models of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31
Pharmacotherapy of schi­zophrenia: clinical and some age-related aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50

To date, numerous data about the genetic variants associated with cognitive impairments in schizophrenia have been accumulated. However, there is still a long way to establishing the genetic basis of the deasease-related cognitive deficit, which will shed light on the biological mechanisms of this syndrome and contribute to the personification of health and social care of patients in the early stages of schizophrenia. It seems that epigenetics will play an important role in achieving these goals. Although epigenetics and epigenetic medicine are in their infancy and only approaching research on the cognitive deficit in schizophrenia, they have already provided a number of interesting data that evidence the role of epigenetic modifications in the development of the disease and expand our understanding of the mechanisms of genotype-environment interactions determining the development and functioning of the brain that underlie cognition. We can expect that for such a complex multifactorial trait as the cognitive deficit in schizophrenia epigenetic markers will be more accurate predictors than genetic ones.

Keywords:

schizophrenia
epigenetics
pharmacoepigenetics
cognitive deficit

Authors:

Alfimova M.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Kondratyev N.V.

Mental Health Research Center, Moscow, Russia

Golimbet V.E.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

List of references:

  1. Wolffe A. Epigenetics: Regulation Through Repression. Science. 1999;286(5439):481-486. doi:10.1126/science.286.5439.481
  2. Josse J, Kaiser AD, Kornberg A. Enzymatic synthesis of deoxyribonucleic acid: VIII. Frequencies of nearest neighbor base sequencesin deoxyribonucleic acid. Journal of Biological Chemistry. 1961;236:864-875.
  3. Ehrlich M, Gama-Sosa M, Huang L et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucl Acids Res. 1982;10(8):2709-2721. doi:10.1093/nar/10.8.2709
  4. Lavrov S, Kibanov M. Noncoding RNAs and chromatin structure. Biochemistry Moscow. 2007;72(13):1422-1438. (In Russ.). doi:10.1134/s0006297907130020
  5. Graff J, Kim D, Dobbin M, Tsai L. Epigenetic Regulation of Gene Expression in Physiological and Pathological Brain Processes. Physiological Reviews. 2011;91(2):603-649. doi:10.1152/physrev.00012.2010
  6. Petronis A, Paterson A, Kennedy J. Schizophrenia: An Epigenetic Puzzle? Schizophrenia Bulletin. 1999;25(4):639-655. doi:10.1093/oxfordjournals.schbul.a033408
  7. Ibi D, González-Maeso J. Epigenetic signaling in schizophrenia. Cellular Signalling. 2015;27(10):2131-2136. doi:10.1016/j.cellsig.2015.06.003
  8. Ripke S, Neale B, Corvin A et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427. doi:10.1038/nature13595
  9. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience. 2015;18(2):199-209. doi:10.1038/nn.3922
  10. Curtis D. Pathway analysis of whole exome sequence data provides further support for the involvement of histone modification in the aetiology of schizophrenia. Psychiatric Genetics. 2016;1. doi:10.1097/ypg.0000000000000132
  11. Petronis A, Gottesman I, Kan P et al. Monozygotic Twins Exhibit Numerous Epigenetic Differences: Clues to Twin Discordance? Schizophrenia Bulletin. 2003;29(1):169-178. doi:10.1093/oxfordjournals.schbul.a006988
  12. Dempster E, Pidsley R, Schalkwyk L et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Human Molecular Genetics. 2011;20(24):4786-4796. doi:10.1093/hmg/ddr416
  13. Bönsch D, Wunschel M, Lenz B, Janssen G, Weisbrod M, Sauer H. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Research. 2012;198(3):533-537. doi:10.1016/j.psychres.2011.09.004
  14. Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review. BMC Genetics. 2016;17(1):27. doi:10.1186/s12863-016-0332-2
  15. Wockner L, Noble E, Lawford B et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Translational Psychiatry. 2014;4(1):339. doi:10.1038/tp.2013.111
  16. Matrisciano F, Panaccione I, Grayson D, Nicoletti F, Guidotti A. Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review. Current Neuropharmacology. 2016;14(1):41-47. doi:10.2174/1570159x13666150713174242
  17. Rudenko A, Tsai LH. Epigenetic modifications in the nervous system and their impact upon cognitive impairments. Neuropharmacology. 2014;80:70-82. doi:0.1016/j.neuropharm.2014.01.043a
  18. Bonnaud E, Suberbielle E, Malnou C. Histone acetylation in neuronal (dys)function. Biomolecular Concepts. 2016;7(2). doi:10.1515/bmc-2016-0002
  19. Diwadkar V, Bustamante A, Rai H, Uddin M. Epigenetics, Stress, and Their Potential Impact on Brain Network Function: A Focus on the Schizophrenia Diatheses. Frontiers in Psychiatry. 2014;5. doi:10.3389/fpsyt.2014.00071
  20. Bock J, Wainstock T, Braun K, Segal M. Stress in Utero: Prenatal Programming of Brain Plasticity and Cognition. Biological Psychiatry. 2015;78(5):315-326. doi:10.1016/j.biopsych.2015.02.036
  21. McGowan PO, Roth TL. Epigenetic pathways through which experiences become linked with biology. Developmental Psychopathology. 2015;27(2):637-648. doi:10.1017/S0954579415000206
  22. Lubin F. Epigenetic gene regulation in the adult mammalian brain: Multiple roles in memory formation. Neurobiology of Learning and Memory. 2011;96(1):68-78. doi:10.1016/j.nlm.2011.03.001
  23. Zovkic I, Guzman-Karlsson M, Sweatt J. Epigenetic regulation of memory formation and maintenance. Learning & Memory. 2013;20(2):61-74. doi:10.1101/lm.026575.112
  24. Zheutlin AB, Viehman RW, Fortgang R et al. Cognitive endophenotypes inform genome-wide expression profiling in schizophrenia. Neuropsychology. 2016;30(1):40-52. doi:10.1037/neu0000244
  25. Liu J, Bann C, Lester B et al. Neonatal Neurobehavior Predicts Medical and Behavioral Outcome. Pediatrics. 2009;125(1):90-98. doi:10.1542/peds.2009-0204
  26. Lesseur C, Paquette A, Marsit C. Epigenetic Regulation of Infant Neurobehavioral Outcomes. Medical Epigenetics. 2014;2(2):71-79. doi:10.1159/000361026
  27. Lillycrop K, Costello P, Teh A et al. Association between perinatal methylation of the neuronal differentiation regulator HES1 and later childhood neurocognitive function and behaviour. International Journal of Epidemiology. 2015;44(4):1263-1276. doi:10.1093/ije/dyv052
  28. Mather KA, Kwok JB, Armstrong N, Sachdev PS. The role of epigenetics in cognitive ageing. International Journal of Geriatric Psychiatry. 2014;29(11):1162-1171. doi:10.1002/gps.4183
  29. Labouesse M, Dong E, Grayson D, Guidotti A, Meyer U. Maternal immune activation induces GAD1 and GAD2 promoter remodeling in the offspring prefrontal cortex. Epigenetics. 2015;10(12):1143-1155. doi:10.1080/15592294.2015.1114202
  30. Xu J, He G, Zhu J et al. Prenatal Nutritional Deficiency Reprogrammed Postnatal Gene Expression in Mammal Brains: Implications for Schizophrenia. International Journal of Neuropsychopharmacology. 2014;18(4):054. doi:10.1093/ijnp/pyu054
  31. Ursini G, Cavalleri T, Fazio L et al. BDNF rs6265 methylation and genotype interact on risk for schizophrenia. Epigenetics. 2016;11(1):11-23. doi:10.1080/15592294.2015.1117736
  32. Ursini G, Bollati V, Fazio L et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. Journal of Neuroscience. 2011;31(18):6692-6698. doi:10.1523/JNEUROSCI.6631-10.2011
  33. Walton E, Liu J, Hass J et al. MB-COMT promoter DNA methylation is associated with working-memory processing in schizophrenia patients and healthy controls. Epigenetics. 2014;9(8):1101-1107. doi:10.4161/epi.29223
  34. Rubin L, Connelly J, Reilly J et al. Sex and Diagnosis-Specific Associations Between DNA Methylation of the Oxytocin Receptor Gene With Emotion Processing and Temporal-Limbic and Prefrontal Brain Volumes in Psychotic Disorders. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2016;1(2):141-151. doi:10.1016/j.bpsc.2015.10.003
  35. Negrón-Oyarzo I, Lara-Vásquez A, Palacios-García I, Fuentealba P, Aboitiz F. Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior. Biological Research. 2016;49(1):16. doi:10.1186/s40659-016-0076-5
  36. Leeson VC, Sharma P, Harrison M, Ron MA, Barnes TR, Joyce EM. IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. Schizophrenia Bulletin. 2011;37(4):768-777. doi:10.1093/schbul/sbp143
  37. Gurovich IYa, Shmukler AB, Zaitseva YuS. Dynamics of neurocognitive functioning in patients in early stages of schizophrenia and schizophrenia spectrum disorders. Zhurnal Nevrologii I Psikhiatrii im S.S. Korsakova. 2012;112(8):7-14. (In Russ.).
  38. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028. doi:10.1016/j.neuropsychologia.2009.03.004
  39. Nithianantharajah J, Hannan A. Mechanisms mediating brain and cognitive reserve: Experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(2):331-339. doi:10.1016/j.pnpbp.2010.10.026
  40. Fischer A. Environmental enrichment as a method to improve cognitive function. What can we learn from animal models? Neuro Image. 2016;131:42-47. doi:10.1016/j.neuroimage.2015.11.039
  41. Griñan-Ferré C, Pérez-Cáceres D, Gutiérrez-Zetina S et al. Environmental Enrichment Improves Behavior, Cognition, and Brain Functional Markers in Young Senescence-Accelerated Prone Mice (SAMP8). Molecular Neurobiology. 2015;53(4):2435-2450. doi:10.1007/s12035-015-9210-6
  42. Wu J, Bie B, Naguib M. Epigenetic Manipulation of Brain-derived Neurotrophic Factor Improves Memory Deficiency Induced by Neonatal Anesthesia in Rats. Anesthesiology. 2016;124(3):624-640. doi:10.1097/ALN.0000000000000981
  43. Neidl R, Schneider A, Bousiges O et al. Late-Life Environmental Enrichment Induces Acetylation Events and Nuclear Factor κB-Dependent Regulations in the Hippocampus of Aged Rats Showing Improved Plasticity and Learning. Journal of Neuroscience. 2016;36(15):4351-4361. doi:10.1523/JNEUROSCI.3239-15.2016
  44. Yu CC, Furukawa M, Kobayashi K et al. Genome-wide DNA methylation and gene expression analyses of monozygotic twins discordant for intelligence levels. PLoS One. 2012;7(10):47081. doi:10.1371/journal.pone.0047081
  45. Córdova-Palomera A, Fatjó-Vilas M, Kebir O, Gastó C, Krebs MO, Fañanás L. Polymorphic variation in the epigenetic gene DNMT3B modulates the environmental impact on cognitive ability: a twin study. European Psychiatry. 2015;30(2):303-308. doi:10.1016/j.eurpsy.2014.11.011
  46. Stein JL, Medland SE, Vasquez AA et al. Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics. 2012;44(5):552-561. doi:10.1038/ng.2250
  47. Alelú-Paz R, González-Corpas A, Ashour N et al. DNA methylation pattern of gene promoters of major neurotransmitter systems in older patients with schizophrenia with severe and mild cognitive impairment. International Journal of Geriatric Psychiatry. 2015;30(6):558-565. doi:10.1002/gps.4182
  48. Muir W, McKechanie A. Can epigenetics help in the discovery of therapeutics for psychiatric disorders, especially schizophrenia? Expert Opinion on Drug Discovery. 2009;4(6):621-627. doi:10.1517/17460440902895446
  49. Bosia M, Pigoni A, Cavallaro R. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opinion on Drug Discovery. 2015;10(2):125-139. doi:10.1517/17460441.2015.976552
  50. Niwa M, Lee R, Tanaka T, Okada K, Kano S, Sawa A. A critical period of vulnerability to adolescent stress: epigenetic mediators in mesocortical dopaminergic neurons. Human Molecular Genetics. 2016;25(7):1370-1381. doi:10.1093/hmg/ddw019
  51. Brami-Cherrier K, Anzalone A, Ramos M et al. Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits. Molecular Psychiatry. 2014;19(11):1193-1200. doi:10.1038/mp.2014.67.
  52. Peedicayil J. Epigenetic Drugs in Cognitive Disorders. CPD. 2014;20(11):1840-1846. doi:10.2174/13816128113199990526
  53. Shrestha S, Offer S. Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy. Medical Epigenetics. 2016;4(1):1-19. doi:10.1159/000444713
  54. Cha DS, Kudlow PA, Baskaran A, Mansur RB, McIntyre RS. Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia. Neuropharmacology. 2014;77:481-486. doi:10.1016/j.neuropharm.2013.08.038
  55. Weïwer M, Lewis M, Wagner F, Holson E. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Medicinal Chemistry. 2013;5(13):1491-1508. doi:10.4155/fmc.13.141
  56. Day J, Sweatt J. Epigenetic Mechanisms in Cognition. Neuron. 2011;70(5):813-829. doi:10.1038/npp.2011.85
  57. Boks M, de Jong N, Kas M et al. Current status and future prospects for epigenetic psychopharmacology. Epigenetics. 2012;7(1):20-28. doi:10.4161/epi.7.1.18688
  58. Vojta A, Dobrinić P, Tadić V et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Research. 2016;159. doi:10.1093/nar/gkw159
  59. Houston I, Peter CJ, Mitchell A, Straubhaar J, Rogaev E, Akbarian S. Epigenetics in the human brain. Neuropsychopharmacology.2013;38(1):183-197. doi:10.1038/npp.2012.78

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.